PT-141
Also known as: Bremelanotide
Quick summary
A cyclic peptide derived from melanotan II that acts on melanocortin receptors in the brain. Research focus: melanocortin receptor pharmacology and central sexual-desire pathways. This page leads with SRP's low-and-slow starting dose.
2D structure
Overview
A cyclic peptide derived from melanotan II that acts on melanocortin receptors in the brain. It went through Phase 3 trials, so a lot of the published data comes from human studies.
Looking for research material? Simple Research Peptides lists PT-141 10 mg Melanocortin Research Peptide Vial for laboratory research use.
Mechanism
A cyclic melanocortin agonist that acts mainly at the MC3 and MC4 receptors in the central nervous system.
Research areas
- melanocortin receptor pharmacology
- central sexual-desire pathways
Storage & reconstitution
Typically supplied as a lyophilized powder; keep sealed vials cold (refrigerated short term, frozen for long-term holding) and away from light. Laboratories commonly reconstitute with bacteriostatic or sterile water, swirling gently rather than shaking, and keep the solution refrigerated, using it within a few weeks.
Recommended starting dose (low and slow)
| Starting dose | PT-141 is taken as needed. Ranges begin at 0.5-1 mg (500 mcg, 0.5 mg, 1 mg, 0.75 mg). |
|---|---|
| Frequency | Reported schedules: as needed, 45min–2h before activity; As needed in studies; As needed. |
| Reconstitution | Examples: 10 mg vial + 2 mL bacteriostatic water = 5 mg/mL; 10 mg vial + 2 mL water = 5 mg/mL; 10mg vial + 2mL diluent (as listed). storage note: Reconstituted: refrigerate, used within 4–6 weeks. |
Studied higher doses
Studies have used doses up to the amounts below. Higher doses can be dangerous. Whether a person can reach them safely depends on height, weight, activity level, training and pre-existing conditions. We recommend following the lower starting dose above, and contacting SRP with any questions.
| Highest amount reported in studies | 2 mg per dose in; 1.75 mg; 1.75 mg. The approved product (bremelanotide) dose in the phase 3 RECONNECT trials (Obstet Gynecol 2019, confirmed) was 1.75 mg as needed. quotes up to 2.5 mg (and 0.3-10 mg across studies) - conflict. a label limit of 8 doses a month. |
|---|---|
| Step-up schedules reported | No titration: single as-needed doses. supply math follows the approved product's cap of 8 doses per month. |
Route and timing
Route: Subcutaneous injection; intranasal forms have also been studied.
Timing: Pending - to be added by SRP
Cycle length and repeat
Pending - to be added by SRP
Half-life
Approximate, for Bobby's review: About 2 to 3 hours.
Side effects
Pending - to be added by SRP
Suggested bloodwork and monitoring
Draft, for Bobby's review: CBC and comprehensive metabolic panel (kidney and liver function, electrolytes) before starting and again after a few weeks; blood pressure readings; relevant reproductive hormones.
Cautions
Pending - to be added by SRP
Reconstitution calculator
Math aid only. It converts the numbers you enter; it is not dosing advice. For research use only. Prefilled with this page's vial size, reconstitution and low-and-slow starting dose where known; change any value.
Frequently asked questions
What is PT-141 studied for?
In research it is studied for melanocortin receptor pharmacology and central sexual-desire pathways. A cyclic melanocortin agonist that acts mainly at the MC3 and MC4 receptors in the central nervous system.
How is PT-141 given in research?
Subcutaneous injection; intranasal forms have also been studied. See the dosing frequency block on this page for how often.
What amount should a researcher start with?
This page lists SRP's low-and-slow starting dose in the Recommended starting dose section. Higher amounts that appear in studies are listed separately with their safety context. Start with the lower dose and contact SRP with any questions.
Related peptides
Last updated: October 19, 2026